About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5892 record(s)
Req # A-2024-000046
Any Canadian Reference Product Confirmation submitted by the sponsor of the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000050
If the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) has received, a Screening Acceptance Letter, a Notice of Deficiency (NOD), a Notice of Non-Compliance (NON), a NOD-Withdrawal (NODW), a NON-Withdrawal (NON-W), provide the month and…Organization: Health Canada
May 2024
Req # A-2024-000051
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Fourth Desmopressin ANDS.Organization: Health Canada
May 2024
Req # A-2024-000052
In respect of the desmopressin acetate submission which was removed from the Generic Submissions Under Review (GSUR) List some time between February 22, 2024 and March 18, 2024, the year and month in which the Abbreviated New Drug Submission (ANDS)…Organization: Health Canada
May 2024
Req # A-2024-000053
The Product Information Template: Regulatory Enrollment Process for the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) , setting out the proposed indication(s)/use(s) of the drug product.Organization: Health Canada
May 2024
Req # A-2024-000054
The name of the company who submitted the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000055
In respect of the desmopressin acetate submission which was removed from the Generic Submissions Under Review (GSUR) List some time between February 22, 2024 and March 18, 2024, any correspondence between Health Canada and the company who submitted…Organization: Health Canada
May 2024
Req # A-2024-000072
Records of communication between employees or appointed politicians working collaboratively with or for Health Canada, and staff or appointed politicians in the Australian Government regarding sodium monofluoroacetate. Between January 1 2021 and…Organization: Health Canada
May 2024
Req # A-2024-000079
All correspondence between registered lobbyist Sheila Copps and Health Canada employee David Boudreau between January 1, 2020, and December 31, 2022.Organization: Health Canada
May 2024
Req # A-2024-000086
Documents evidencing the involvement of private consulting firms in: The review process conducted by Health Canada for Messenger Ribonucleic Acid (mRNA) vaccines against COVID-19, between June 2, 2021, and December 31, 2022. All communications by…Organization: Health Canada
May 2024